Risk Factors

Hereditary AT deficiency is autosomal dominant; each offspring has a 50% chance of inheriting the condition.^1,2

Men and women are affected equally.^1,2

The figure below represents a hypothetical family tree.

Dominant Inheritance Can Affect Generations

Who is Affected?

Hereditary AT deficiency affects 1 in 2000 to 5000 individuals^3,4
An incidence of 1 in 5000 would suggest that there are at least 60,000 affected people in the United States⁵
Hereditary AT deficiency was the first hereditary thrombophilia associated with increased risk of thromboembolism^1,6
It was originally identified in 1965 by Egeberg, who described members of a Norwegian family, many of whom had plasma AT levels of approximately 50% of normal (as determined by AT activity) and some of whom experienced recurrent thromboembolism^2,6

References:

Franchini M, Veneri D, Salvagno GL, Manzato F, Lippi G. Inherited thrombophilia. Crit Rev Clin Lab Sci. 2006;43(3):249-290.
Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh.
1965;13:516-530.
Bucur SZ, Levy JH, Despotis GJ, Spiess BD, Hillyer CD. Use of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion. 1998;38(5):481-498.
Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med. 1975;292(3):146-151.
US Census Bureau, Population Division. US and World Population Clocks – POPClocks. http://www.census.gov/main/www/popclock.html. Revised November 22, 2006. Updated January 31, 2008. Accessed April 9, 2009.
Kottke-Marchant K, Duncan JA. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med. 2002;126(11)1326-1336.

Important Safety Information

Thrombate III is indicated for the treatment of patients with hereditary antithrombin deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.

In clinical studies with Thrombate III, the most common side effects were dizziness, chest tightness, nausea, and foul taste in the mouth.

The anticoagulant effect of heparin is enhanced by concurrent treatment with Thrombate III in patients with hereditary AT-III deficiency. Thus, in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with Thrombate III.

Thrombate III is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Individuals who receive infusions of blood or blood plasma may develop signs and/or symptoms of some viral infections, particularly hepatitis C.

Please speak to your doctor and refer to Thrombate III Prescribing Information for full details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.